BioCryst Pharmaceuticals
BCRX

$7.98

1.6%

Market Cap: $1.65B

About: BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.

Employees: 531

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,686 funds

0

Analysts bullish %

of 4 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

25% more repeat investments, than reductions

Existing positions increased: 84 | Existing positions reduced: 67

20% more funds holding in top 10

Funds holding in top 10: 5 [Q1] → 6 (+1) [Q2]

16% more capital invested

Capital invested by funds: $931M [Q1] → $1.08B (+$146M) [Q2]

3% more first-time investments, than exits

New positions opened: 41 | Existing positions closed: 40

0% more funds holding

Funds holding: 236 [Q1] → 237 (+1) [Q2]

3% less call options, than puts

Call options by funds: $8.76M | Put options by funds: $9.04M

4.37% less ownership

Funds ownership: 88.81% [Q1] → 84.44% (-4.37%) [Q2]

See Fund Rankings

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$7

12%

downside

Avg. target

$15.75

97%

upside

High target

$30

276%

upside

4 analyst ratings

3 positive

75%

1 neutral

25%

0 negative

0%

JMP Securities Jonathan Wolleben 42% 1-year accuracy 30 / 71 met price target	101%upside $16	Market Outperform Maintained	6 Aug 2024
Barclays Gena Wang 42% 1-year accuracy 10 / 24 met price target	12%downside $7	Equal-Weight Maintained	6 Aug 2024
RBC Capital Brian Abrahams 52% 1-year accuracy 39 / 75 met price target	25%upside $10	Outperform Reiterated	6 Aug 2024
HC Wainwright & Co. Andrew Fein 46% 1-year accuracy 77 / 166 met price target	276%upside $30	Buy Reiterated	6 Aug 2024

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about BCRX published over the past 30 days

BioCryst Presents New ORLADEYO® (berotralstat) Data at 7th Bradykinin Symposium

RESEARCH TRIANGLE PARK, N.C., Sept. 06, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the presentation of six posters, including the first interim real-word evidence from the APeX-N trial, and new data highlighting the value of shared decision making (SDM) between healthcare providers (HCPs) and their hereditary angioedema (HAE) patients to provide optimal patient outcomes.

BioCryst Presents New ORLADEYO® (berotralstat) Data at 7th Bradykinin Symposium

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., Sept. 04, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted nine newly-hired employees stock options to purchase an aggregate of 28,400 shares, and restricted stock units (RSUs) covering an aggregate of 20,025 shares, of BioCryst common stock. The options and RSUs were granted as of August 30, 2024, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BioCryst to Present at Upcoming Investor Conferences

RESEARCH TRIANGLE PARK, N.C., Aug. 22, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the following conferences:

BioCryst to Present at Upcoming Investor Conferences

BioCryst Pharmaceuticals, Inc. (BCRX) Q2 2024 Earnings Call Transcript

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX ) Q2 2024 Earnings Call Transcript August 5, 2024 8:30 AM ET Company Participants John Bluth - Chief Communications Officer Jon Stonehouse - CEO Charlie Gayer - Chief Commercial Officer Anthony Doyle - CFO Helen Thackray - Chief R&D Officer Conference Call Participants Tazeen Ahmad - Bank of America Brian Abrahams - RBC Capital Markets Chris Raymond - Piper Sandler Gena Wang - Barclays Maury Raycroft - Jefferies Stacy Ku - TD Cowen Jon Wolleben - JMP Securities Serge Belanger - Needham & Company Operator Good day and welcome to the BioCryst Second Quarter 2024 Earnings Call. All participants will be in listen-only mode.

BioCryst Pharmaceuticals, Inc. (BCRX) Q2 2024 Earnings Call Transcript

Zacks Investment Research

Can BioCryst (BCRX) Climb 99.43% to Reach the Level Wall Street Analysts Expect?

The mean of analysts' price targets for BioCryst (BCRX) points to a 99.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Can BioCryst (BCRX) Climb 99.43% to Reach the Level Wall Street Analysts Expect?

Zacks Investment Research

BioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Tops Revenue Estimates

BioCryst Pharmaceuticals (BCRX) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.24 per share a year ago.

BioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Tops Revenue Estimates

BioCryst Reports Second Quarter 2024 Financial Results and Provides Business Update

—Q2 2024 ORLADEYO net revenue grows 34 percent y-o-y to $108.3 million— —Full-year 2024 ORLADEYO revenue guidance increased to $420-$435 million (previously $390-$400 million)— —Company generates GAAP operating profit of $8.8 million in second quarter ($21.9 million non-GAAP operating profit)— —Pipeline continues to advance— RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported financial results for the second quarter ended June 30, 2024, and provided a corporate update.

BioCryst Reports Second Quarter 2024 Financial Results and Provides Business Update

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., Aug. 02, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted nine newly-hired employees stock options to purchase an aggregate of 40,350 shares, and restricted stock units (RSUs) covering an aggregate of 28,200 shares, of BioCryst common stock. The options and RSUs were granted as of July 31, 2024, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

7 Small-Cap Stocks to Buy for Large-Scale Gains

Small-capitalization companies represent high-risk endeavors. At the same time, they generally carry higher reward potential.

7 Small-Cap Stocks to Buy for Large-Scale Gains

Zacks Investment Research

Will BioCryst Pharmaceuticals (BCRX) Report Negative Earnings Next Week? What You Should Know

BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will BioCryst Pharmaceuticals (BCRX) Report Negative Earnings Next Week? What You Should Know

See News Rankings